Highlights

  • SomnoMed (ASX:SOM) develops custom-fitted oral appliances for obstructive sleep apnoea.
  • The company’s Continuous Open Airway Therapy approach provides an alternative device-based treatment option.
  • FY2026 results showed Revenue growth and improved underlying EBITDA.
  • Regional performance, Leadership changes and market competition remain key areas to monitor.

SomnoMed Limited (ASX:SOM) is a medical device company focused on oral appliance solutions for obstructive sleep apnoea. The company develops custom-fitted devices designed to help maintain airway openness during sleep. This article reviews SomnoMed’s Business model, financial progress and the factors shaping its next phase of development.

Oral Appliance Approach to Sleep Apnoea

SomnoMed’s devices use a Continuous Open Airway Therapy (COAT) approach, where custom-made oral appliances position the lower jaw forward to help keep the airway open during sleep.

The technology is designed for patients who may not tolerate continuous positive airway pressure (CPAP) devices or who require alternative treatment options. The company operates within the broader sleep health market, where treatment adherence remains an important consideration.

Financial Performance and Regional Trends

For the twelve months to 30 June 2026, SomnoMed reported revenue of A$114.5 million, while underlying Earnings before interest, tax, Depreciation and Amortisation (EBITDA) increased to A$10.9 million.

Regional performance varied during the period. North America recorded growth, while Europe remained relatively stable and Asia-Pacific experienced softer conditions.

The results reflect the importance of regional execution, referral networks and healthcare provider relationships in the medical device sector.

Business Development and Market Factors

SomnoMed continues to develop its oral appliance business by supporting clinicians and patients through its device ecosystem. Growth depends on awareness of oral appliance treatment, healthcare provider referrals and reimbursement arrangements.

The company also operates in a competitive environment where CPAP remains an established treatment approach and other sleep-related technologies continue to develop.

Leadership and Future Priorities

SomnoMed experienced leadership changes during 2026, including changes to senior management roles. Maintaining operational continuity and supporting regional growth remain important considerations following these changes.

Future priorities include sustaining Demand across key markets, improving cash generation and continuing development of the company’s medical device platform.

Key Insights

SomnoMed has established a specialised position in oral appliance treatment for sleep apnoea. The company’s future progress will depend on continued adoption of its devices, regional execution and its ability to operate effectively within a competitive healthcare market.